Chimerix Inc
CMRXDelisted Apr 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001117480
Chimerix Inc was delisted on Apr 21, 2025; its insiders filed their last Form 4 on Apr 21, 2025; 119 institutions reported holding it in 13F filings for Q1 2025, worth $618.1M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Chimerix Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Chimerix Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Demski Martha J | Director | 0Indirect | Apr 21, 2025 | 0 |
| Kozin Marc D | Director | – | Apr 21, 2025 | 0 |
| Middleton Fred A | Director | 0 | Apr 21, 2025 | 0 |
| Alrutz Michael Albert | SVP AND GENERAL COUNSEL | 0 | Apr 21, 2025 | 0 |
| Sherman Michael A. | Chief Executive Officer | 0 | Apr 21, 2025 | 0 |
| Multani Pratik S | Director | – | Apr 21, 2025 | 0 |
| Andriole Michael T. | PRESIDENT AND CEO | 0 | Apr 21, 2025 | 0 |
| Riga Thomas J | COO and CCO | 0 | Apr 21, 2025 | 0 |
| Meyer Robert J. | Director | 0 | Apr 21, 2025 | 0 |
| Jakeman David | VP OF FINANCE AND ACCOUNTING | 0 | Apr 21, 2025 | 0 |
| Decker Lisa Lynn | Director | – | Apr 21, 2025 | 0 |
| Melemed Allen S. | CHIEF MEDICAL OFFICER | 0 | Apr 21, 2025 | 0 |
| Vakiener Victoria | Director | – | Apr 21, 2025 | 0 |
| LaSpaluto Michelle | CHIEF FINANCIAL OFFICER | 0 | Apr 21, 2025 | 0 |
| Machado Patrick | Director | – | Jun 12, 2023 | 0 |
| Gilliss Catherine | Director | – | Jun 12, 2023 | 0 |
| Cantex Pharmaceuticals, Inc. | 10% Owner | 3,500,000 | Sep 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | Melemed Allen S.CHIEF MEDICAL OFFICER | SSale | −3.06K | $4.50 | −$13.8K | −2.0%152.9K after | |
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | Andriole Michael T.PRESIDENT AND CEO | SSale | −7.37K | $4.52 | −$33.3K | −1.2%609.6K after | |
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | Alrutz Michael AlbertSVP AND GENERAL COUNSEL | SSale | −1.60K | $4.52 | −$7.23K | −0.7%213.6K after | |
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | Jakeman DavidVP OF FINANCE AND ACCOUNTING | SSale | −300 | $4.53 | −$1.36K | −0.2%149.0K after | |
| Feb 14, 2025 (view filing) | Feb 13 | 1 day | LaSpaluto MichelleCHIEF FINANCIAL OFFICER | SSale | −2.26K | $4.51 | −$10.2K | −1.3%173.0K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Jakeman DavidVP OF FINANCE AND ACCOUNTING | SSale | −2.80K | $4.10 | −$11.5K | −1.8%149.3K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | LaSpaluto MichelleCHIEF FINANCIAL OFFICER | SSale | −1.01K | $4.11 | −$4.17K | −0.6%175.2K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Andriole Michael T.PRESIDENT AND CEO | SSale | −2.35K | $4.10 | −$9.63K | −0.4%617.0K after | |
| Aug 9, 2024 (view filing) | Aug 8 | 1 day | Andriole Michael T.PRESIDENT AND CEO | SSale | −1.28K | $0.83 | −$1.07K | −0.3%462.5K after | |
| Feb 16, 2024 (view filing) | Feb 14 | 2 days | Andriole Michael T.PRESIDENT AND CEO | SSale | −1.74K | $1.04 | −$1.81K | −0.4%447.0K after | |
| Feb 16, 2024 (view filing) | Feb 14 | 2 days | LaSpaluto MichelleCHIEF FINANCIAL OFFICER | SSale | −1.94K | $1.04 | −$2.02K | −1.7%111.0K after | |
| Feb 16, 2024 (view filing) | Feb 14 | 2 days | Jakeman DavidVP OF FINANCE AND ACCOUNTING | SSale | −2.66K | $1.04 | −$2.77K | −1.8%141.2K after | |
| Nov 20, 2023 (view filing) | Nov 17 | 3 days | Middleton Fred ADirector | PPurchase | +17.3K | $0.96 | +$16.6K | +20.9%100.0K after | |
| Nov 13, 2023 (view filing) | Nov 10 | 3 days | Middleton Fred ADirector | PPurchase | +2.71K | $0.92 | +$2.49K | +3.4%82.7K after | |
| Sep 28, 2023 (view filing) | Sep 28 | Same day | Jakeman DavidVP of Finance and Accounting | SSale | −3.61K | $0.99 | −$3.57K | −2.6%133.1K after | |
| Sep 26, 2023 (view filing) | Sep 25 | 1 day | Middleton Fred ADirector | PPurchase | +20.0K | $0.98 | +$19.6K | +33.3%80.0K after | |
| May 19, 2023 (view filing) | May 18 | 1 day | Andriole Michael T.Chief Business Officer and CFO | PPurchase | +51.7K | $1.14 | +$58.9K | +16.9%357.0K after | |
| May 16, 2023 (view filing) | May 12 | 4 days | Sherman Michael A.Chief Executive Officer | PPurchase | +87.0K | $1.12 | +$97.6K | New position87.0K after | 2 lots |
| May 11, 2023 (view filing) | May 10 | 1 day | Demski Martha JDirector | PPurchase | +18.0K | $1.11 | +$20.0K | +33.3%72.1K after | |
| May 10, 2023 (view filing) | May 8 | 2 days | Meyer Robert J.Director | PPurchase | +8.75K | $1.14 | +$9.97K | +33.1%35.1K after | |
| Mar 29, 2023 (view filing) | Mar 28 | 1 day | Middleton Fred ADirector | PPurchase | +20.0K | $1.21 | +$24.2K | +50.0%60.0K after | |
| Jan 26, 2023 (view filing) | Jan 26 | Same day | Jakeman DavidPrincipal Accounting Officer | SSale | −3.23K | $1.76 | −$5.68K | −2.3%136.8K after | |
| Oct 3, 2022 (view filing) | Sep 29 | 4 days | Middleton Fred ADirector | PPurchase | +20.0K | $1.86 | +$37.2K | +100.0%40.0K after | |
| Sep 30, 2022 (view filing) | Sep 29 | 1 day | Jakeman DavidPrincipal Accounting Officer | SSale | −4.40K | $1.86 | −$8.18K | −3.3%127.5K after | |
| May 20, 2022 (view filing) | May 19 | 1 day | Middleton Fred ADirector | PPurchase | +20.0K | $2.04 | +$40.8K | New position20.0K after | |
| May 20, 2022 (view filing) | May 19 | 1 day | Meyer Robert J.Director | PPurchase | +11.4K | $2.06 | +$23.5K | +76.0%26.4K after | 2 lots |
| May 18, 2022 (view filing) | May 17 | 1 day | Andriole Michael T.Chief Business Officer and CFO | PPurchase | +15.0K | $1.71 | +$25.6K | +7.6%212.7K after | |
| May 17, 2022 (view filing) | May 17 | Same day | Demski Martha JDirector | PPurchase | +10.0K | $1.61 | +$16.1K | +22.7%54.1K after | |
| Feb 4, 2022 (view filing) | Feb 4 | Same day | Jakeman DavidPrincipal Accounting Officer | SSale | −3.30K | $5.56 | −$18.3K | −2.7%117.7K after | |
| Sep 30, 2021 (view filing) | Sep 30 | Same day | Jakeman DavidPrincipal Accounting Officer | SSale | −4.59K | $6.19 | −$28.4K | −4.1%106.1K after | |
| Sep 16, 2021 (view filing) | Sep 14 | 2 days | Cantex Pharmaceuticals, Inc.10% Owner | SSaleCommon Stock, par value $0.001 | −6.50M | $5.75 | −$37.4M | −65.0%3.50M after |